70
Participants
Start Date
May 30, 2006
Primary Completion Date
March 16, 2012
Study Completion Date
December 10, 2012
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies
Sorafenib Tosylate
Given orally
Columbia University/Herbert Irving Cancer Center, New York
State University of New York Upstate Medical University, Syracuse
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
National Institutes of Health Clinical Center, Bethesda
University of Alabama at Birmingham Cancer Center, Birmingham
St. Jude Children's Research Hospital, Memphis
Cincinnati Children's Hospital Medical Center, Cincinnati
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
Riley Hospital for Children, Indianapolis
C S Mott Children's Hospital, Ann Arbor
Children's Hospital of Wisconsin, Milwaukee
University of Minnesota/Masonic Cancer Center, Minneapolis
Lurie Children's Hospital-Chicago, Chicago
Washington University School of Medicine, St Louis
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Children's Hospital of Orange County, Orange
Lucile Packard Children's Hospital Stanford University, Palo Alto
Oregon Health and Science University, Portland
Seattle Children's Hospital, Seattle
Dana-Farber Cancer Institute, Boston
Hospital for Sick Children, Toronto
Centre Hospitalier Universitaire Sainte-Justine, Montreal
National Cancer Institute (NCI)
NIH